31 results about "Elevated ph" patented technology

There is provided a process for recovery of lignin from a black liquor that contains either soluble or dispersed lignin, generating a “liquid lignin” at high yield. Soluble lignin at elevated pH is precipitated by reducing the pH of the black liquor stream by countercurrent reaction with carbon dioxide, at elevated temperature and pressure, creating two bulk fluid phases: a heavy lignin-rich phase and a light lignin-depleted phase. The heavy lignin-rich phase is separated and washed countercurrently with a strong acid to displace metal cations from the lignin, creating a low-salt lignin, which is then formed into a low-dust high-bulk-density lignin fuel pellet. If needed, especially for lignin recovered from kraft papermaking black-liquor streams, an oxidation step is included to eliminate negative odor for high-value green-chemistry applications.

A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.

A stannous methanesulfonate solution for tin electroplating applications and a method of forming the same are disclosed. The solution has an elevated pH. The solution also has a sufficient tin concentration for electroplating applications.

A pharmaceutical composition comprising proton pump inhibitors and prebiotics is proposed for the treatment of gastric and duodenal ulcer, this allowing effective ulcer treatment and eradication of H. pylori from the gastric and duodenal mucosa to be carried out without using wide-spectrum antibiotics. The comprehensive treatment of ulcer disease associated with a helicobaterial infection using a pharmaceutical composition of a PPI and a prebiotic makes it possible, in conditions of an elevated pH of the stomach contents, actively to stimulate the growth of lactobacilli in the upper sections of the gastrointestinal tract, including the duodenum, and substantially to increase the titre of lactobacilli, which are antagonists of H. pylori, which greatly improves the effectiveness of the ulcer treatment. The high clinical effectiveness and safety resulting from the synergistic action of the proton pump inhibitor and the prebiotic in the upper sections of the gastrointestinal tract, the absence of side effects and recurrences, and also the level of compliance to the combined treatment provided by the claimed pharmaceutical composition indicate that the proposed formulation is a promising new means for the treatment of gastric and duodenal ulcer. Use of the claimed composition dramatically reduces the number of recurrences of the illness.